Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Brain Cancer

Journal Scan / Research · April 26, 2018

Continuous Volume of Residual Enhancement on T1 Subtraction Is Prognostic in Patients With GBM



Additional Info

Disclosure statements are available on the authors' profiles:

Validation of Post-Operative Residual Contrast Enhancing Tumor Volume as an Independent Prognostic Factor for Overall Survival in Newly Diagnosed Glioblastoma
Neuro-oncology 2018 Apr 05;[EPub Ahead of Print], BM Ellingson, LE Abrey, SJ Nelson, TJ Kaufmann, J Garcia, O Chinot, F Saran, R Nishikawa, R Henriksson, WP Mason, W Wick, N Butowski, KL Ligon, ER Gerstner, H Colman, J de Groot, S Chang, I Mellinghoff, RJ Young, BM Alexander, R Colen, JW Taylor, I Arrillaga-Romany, A Mehta, RY Huang, WB Pope, D Reardon, T Batchelor, M Prados, E Galanis, PY Wen, TF Cloughesy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading